Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
Cytomegalovirus (CMV) is the most common opportunistic viral pathogen in solid organ
transplant receptors (SOTR). In Mexico, the experience using generic immunosuppressants have
been demonstrated a wide variation in the pharmacokinetic parameters between generic and
innovative formulation, resulting in a suboptimal absorption of the drug and reaching
infratherapeutic trough levels in blood. In this study the investigators will compare the
pharmacokinetic parameters of innovative and generic valganciclovir in renal transplant
recipients.